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Abstract: Over recent decades, basic research has yielded a large volume of data on many 
potentially clinically relevant genetic determinants of drug efficacy and toxicity. Until 
recently, most examples involved genes encoding drug-metabolizing enzymes, particularly the 
cytochromes P450. More recently, rapid advances in genomic technologies have enabled broader, 
genome-wide searches for determinants of drug response. In parallel with these pharmacogenetic 
studies, a new drug discovery platform, termed pharmacogenomics, has emerged which utilises 
genetic information to guide the selection of new drugs most likely to survive increasingly 
demanding safety and efﬁ  cacy assessments. Together, these advances are widely promoted 
as the basis of a new era of drug-based therapeutics tailored to the individual. The extent to 
which individualized or personalized medicine will emerge as a sustainable new therapeutic 
paradigm is, however, the topic of much debate. It is clear that an increasingly complex series 
of barriers must be overcome if we are to successfully harness genomic advances in the clinical 
setting. Potential barriers may include cost-effectiveness of the test, ethical concerns over the 
use of DNA, and required educational and equipment infrastructure. Although long overdue, 
many of these potential barriers are now being subjected to closer examination and as a result, 
a framework for successful clinical uptake of pharmacogenomics is emerging.
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In recent years, clinical pharmacogenomics has emerged as an umbrella term which 
in, its simplest terms, can be deﬁ  ned as the use of genetic information to improve the 
clinical outcomes of pharmacotherapy. As new technologies, including microarray 
technology, proteomics (proﬁ  ling protein expression) and metabonomics (proﬁ  ling 
small molecule levels), ﬁ  nd their way into the clinical setting, we can anticipate a 
broadening of this deﬁ  nition to the use of biological information to improve the clinical 
outcomes of drug therapy. The aim of pharmacogenomics in the clinical setting is 
simple: to maximize the chances of effective treatment of a speciﬁ  c indication and 
minimise the likelihood of adverse drug reactions. The potential clinical beneﬁ  ts of 
pharmacogenomics are immense and these have been widely articulated and speculated 
in the remarkable number of pharmacogenomics reviews that have been published 
in recent years. These beneﬁ  ts are perhaps most clear with respect to adverse drug 
reactions. Adverse drug reactions are the ﬁ  fth leading cause of death in the United 
States (Lazarou 1998) and represent a major social and ﬁ  nancial burden. Should 
pharmacogenomics be able to make even small inroads into this area, it would clearly 
represent a great ﬁ  nancial and ethical beneﬁ  t to the community at large.
In the substantial literature that has emerged over recent years, pharmacogenomics 
has been widely hyped as having the potential to greatly accelerate the implementation 
of personalized medicine, using therapeutic regimens tailored to each individual’s 
genetic proﬁ  le. Indeed, in many review papers on pharmacogenomics, the general Therapeutics and Clinical Risk Management 2007:3(5) 752
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impression has been that it is just around the corner. However, 
despite the constant press, pharmacogenomics has had little 
utilization in clinical practice (Gardiner and Begg 2005). Of 
late, however, there have been a number of indications that a 
more pragmatic view may be emerging (Phillips et al 2003; 
Tucker 2004).
While acknowledging the relatively limited clinical 
uptake of pharmacogenomics, it is important to note that poor 
clinical implementation of basic pharmacogenomic research 
does not necessarily indicate a failure. Pharmacogenomic 
research can result in other useful outcomes, such as deeper 
insight into the mechanisms and population distributions 
of variance in pharmacotherapy. A better understanding 
of the expected clinical variation can be useful, even in 
the absence of a pharmacogenomic test to predict the 
variance. Furthermore, mechanistic understanding of the 
source of drug variability facilitates the development of 
improved new drugs. As discussed later, pharmaceutical 
companies generally prefer to use pharmacogenomics to 
develop new drugs with improved pharmacology, rather 
than developing pharmacogenomic tests to limit use of their 
drugs in the clinic. While pharmacogenomic research may 
lead to greater understanding of the mechanism leading to 
therapeutic failure or adverse events, testing for genotype 
may not be the best method to use clinically. For example, 
rather than genotyping a particular CYP enzyme, it may be 
preferable to phenotype with a probe substrate or undertake 
therapeutic drug monitoring. A recent survey of clinical 
use of pharmacogenomics in Australia and New Zealand 
found that the most frequently performed genetic test was 
for thiopurine methyltransferase – to predict patients at 
high risk of myelosuppression following standard doses 
of azothiopurine or mercaptopurine (Gardiner and Begg 
2005). However, the frequency of phenotyping exceeded 
genotyping by ﬁ  ve-fold (Gardiner and Begg 2005).
This paper will seek to understand the barriers to the clinical 
implementation of pharmacogenomics. While it is relatively 
simple to enumerate the potential barriers, it is very difﬁ  cult to 
determine which barriers present the most signiﬁ  cant problems. 
Many of these barriers are sufﬁ  cient in isolation to stall imple-
mentation of a pharmacogenomic test. More commonly, 
clinical implementation of pharmacogenomics is inhibited 
by multiple barriers that all need to be addressed before the 
tests can be put into practice. It is difﬁ  cult to delineate the 
optimal path forward under these circumstances and many 
questions arise. Unfortunately, for the most part, there is 
insufﬁ  cient objective research to answer these questions 
fully. While further research on speciﬁ  c pharmacogenomic 
research problems is important, so is research into the ethical, 
political, economic and social issues associated with the 
implementation of clinical pharmacogenomics.
Unraveling the complexities of the factors inﬂ  uencing 
the eventual clinical implementation of pharmacogenomics 
may be best handled by following the general development 
pathway of pharmacogenomic tests from initial conception to 
broad clinical use (Figure 1). At each stage on this pathway, 
there are factors that directly and indirectly inﬂ  uence the 
clinical implementation of pharmacogenomics. The ﬂ  ow of 
topics covered in this review will generally mirror the ﬂ  ow of 
Figure 1. Hence we will initially focus on potential barriers 
encountered early in the development of a pharmacogenomic 
test, and progressively lead into barriers faced during the 
attempt to clinically utilize the pharmacogenomic protocol.
Identiﬁ  cation of speciﬁ  c drug 
phenotypes most amenable
to pharmacogenomic testing
The more cost-effective a pharmacogenomic test is, the more 
likely it will be taken up in the clinical setting. Thus, in order 
to improve clinical implementation of pharmacogenomics, 
it is strategic to focus research on those situations that 
are likely to result in the most cost effective tests. In 
general, it is thought that the cost-effectiveness of health 
care technologies is primarily dependent on the cost and 
effectiveness of the technology, the morbidity and mortality 
associated with the phenotype, and the cost of treating the 
phenotype (Veenstra et al 2000). One study has attempted 
to identify a number of primary characteristics that will 
enhance the cost-effectiveness of pharmacogenomics 
(Veenstra et al 2000). The most appropriate situations 
are those in which the clinical or economic consequences 
are severe and common, and in which current methods 
for monitoring drug response are suboptimal (Veenstra 
et al 2000). Examples of these situations may include 
chronic illnesses requiring extended therapy, therapy 
requiring an extended period before the efﬁ  cacy can be 
assessed, situations in which inappropriate therapy can 
have irreversible consequences and ﬁ  nally, treatments 
associated with severe adverse events that have the potential 
for signiﬁ  cant morbidity (Almuete 2000).
Discovery of a signiﬁ  cant genotype-
phenotype association
Once a particular clinical pharmacotherapy-related 
phenotype has been selected as important, it is necessary to Therapeutics and Clinical Risk Management 2007:3(5) 753
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Figure 1 Idealized ﬂ  ow chart of the processes undertaken to bring pharmacogenomic testing from concept to clinical use.
Discovery of a significant
genotype-phenotype association
Determine reproduciblility
across ethnic populations
Propose a specific model of how
the genotyping will be used to
guide clinical practice
Prospectively collect data to
assess the cost-effectiveness of a
specific pharmacogenomic
protocol vs. the current standard
practice. Preferably a randomized
controlled study
Engagement with and endorsement by the
appropriate stakeholders for use of
pharmacogenomic tests from
Implement pharmacogenomic test in a staged
manner.
Identification of a specific instance in which a better
understanding of the inter-individual variation in
efficacy/toxicity of a drug is likely to result in a significant
financial or clinical improvement.
ﬁ  nd an association between one or more single nucleotide 
polymorphisms (SNPs) and the phenotype. It is known that 
cost-effectiveness of a pharmacogenomics test is generally 
enhanced in situations in which the association between 
genotype and clinical phenotype is strong, and the variant 
allele frequency is relatively high (Veenstra et al 2000).
Scoring the usefulness 
of a SNP-phenotype association
There are many ways to score the usefulness of the asso-
ciation. Commonly used statistics include positive and 
negative predictive power, speciﬁ  city and sensitivity, odds Therapeutics and Clinical Risk Management 2007:3(5) 754
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ratio and relative risk. Perfect associations, resulting in no 
false positives and negatives, are uncommon. Some SNPs 
may allow few false positives at the expense of more false 
negatives, and vice versa. It is necessary to understand the 
clinical consequences of false positives and false negatives 
to judge the utility of any particular SNP. For example, if it is 
imperative to ensure that no one has a serious adverse effect 
from a drug, a test with very high negative predictive power 
(ie, if test is negative, a very high likelihood that the person 
will not have the adverse effect) is called for. The consequence 
of this may be a lower positive predictive power. Thus, there 
will be some patients that could have received the drug, but 
did not get the drug due to a false positive pharmacogenomic 
test. The availability of a good alternative treatment affects 
the relative importance of positive and negative predictive 
power (Tate and Goldstein 2004). It is obvious that assessing 
the utility of various SNPs is complex and requires extensive 
consultation with clinicians.
Experimentally determining genotypes
Setting aside the difﬁ  culty in assessing the absolute and 
relative utility of SNPs for predicting the phenotype, there 
are also many experimental factors that can inﬂ  uence ﬁ  nd-
ing a good SNP as the basis of a pharmacogenomic test. It 
is estimated that there are approximately 6 million common 
SNPs (greater than 10% frequency) among all human popu-
lations and many fold more rare SNPs (Carlson et al 2004). 
The most sensible initial approach is to assess SNPs in genes 
that are known to be associated with the pharmacology of 
the drug. These are typically genes governing the pharmaco-
kinetics of the drug but may also include those inﬂ  uencing 
the pharmacodynamics of the drug or pathogenesis of the 
disease being treated. This approach is commonly known as 
the candidate gene approach and has been the cornerstone of 
the discipline for many years. However, it is highly plausible 
that the observed drug response phenotype is due to a gene 
that has not been previously linked with the pharmacology 
of the drug. This is especially likely for adverse events which 
may be due to trace drug metabolites produced by unknown 
metabolic pathways. Even limiting the search for candidate 
genes to the known pharmacology of a drug can result in a 
very large number of candidate genes when associated gene 
pathways are taken into account, particularly in the case of 
drugs with complex metabolic pathways.
Should analysis of these initial candidate genes prove 
unsuccessful, it may be necessary to turn to highly multi-
plexed technologies for assessing larger numbers of SNPs 
across the genome. Affymetrix’s new Genome-Wide Human 
SNP Array 6.0, which contains 906,600 SNPs and addi-
tional probes to facilitate gene copy number determination. 
Although costs of the chip-based SNP technologies are 
falling, these technologies are still expensive and currently 
out of reach of most researchers and diagnostic settings. 
There are also many issues with data analysis of the rich 
data generated by these approaches. Methods for calling 
genotypes are still in their infancy and it is not clear how 
accurate the calls are. More importantly, there are the issues 
associated with multiple hypothesis testing. P values asso-
ciated with individual tests need to be adjusted to take into 
account the many hypotheses (usually one for each SNP in 
this case) that have been tested (Storey and Tibshirani 2003). 
A failure to do so will give misleading results on which SNPs 
are statistically signiﬁ  cantly associated with the phenotype 
in question.
Some of the problems related to SNP genotyping may 
be alleviated through the use of haplotype approaches which 
aim to limit the number of SNPs warranting analysis. The 
International HapMap project aims to ﬁ  nd tag SNPs that 
identify unique haplotype blocks – DNA sequences that 
are inherited together (International Haplotype Consortium 
2003). With this knowledge, it is thought that the identiﬁ  ca-
tion of a few alleles of a haplotype block can unambiguously 
identify all other polymorphic sites in the region. Recently, 
the ﬁ  rst haplotype map of the human genome emerging from 
the HapMap project was published (International Haplotype 
Consortium 2005). This map provides accurate and complete 
genotypes for more than a million SNPs from four popula-
tions. Recent research suggests that between 65% and 85% 
of the human genome may be organized into haplotype 
blocks of at least 10,000 bases. As a result, researchers need 
to study only about 300,000 to 600,000 tag SNPs to identify 
the haplotypes in the human genome. These tag SNPs should 
hold information on the associated SNPs, thereby reducing 
the number of SNPs to be assessed. The next generation of 
SNP arrays is likely to use the tag SNPs.
Biological limitations of SNPs
It is uncertain whether SNPs in isolation will be able to 
predict most drug response phenotypes sufﬁ  ciently well to 
prove cost-effective. The majority of well known pharma-
cogenomic associations represent predominantly monogenic 
traits with high penetrance and large, discrete functional 
consequence (Nebert et al 2003; Meyer 2004). However, 
drug treatment generally represents a complex phenotype, 
inﬂ  uenced by many genes and environmental factors (Nebert 
2000; Meyer 2004). As a result, the phenotype is commonly a Therapeutics and Clinical Risk Management 2007:3(5) 755
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continuous gradient (Nebert and Vesell 2004). In these cases, 
variation in the activity of multiple major genes, each poten-
tially being insigniﬁ  cant in isolation, must be considered to 
understand the variation in drug response.
Moreover, the activity of these genes may not be predicted 
sufﬁ  ciently by SNPs, in isolation or as haplotypes. Each gene 
may potentially be inﬂ  uenced by endogenous and exogenous 
modiﬁ  ers (Meyer 2004). Phenomena such as gene silencing 
(Schramke and Allshire 2003), epistasis (McGovern et al 
2003), genomic imprinting (Lewis et al 2003), and RNA 
interference may also inﬂ  uence drug response phenotypes 
and need to be considered in addition to SNPs (Nebert et al 
2003). The dynamic nature of the genome, for example, 
alterations in gene expression patterns to compensate for 
perturbation of a gene product or presence of environmental 
stimulus, adds additional complexity to the situation (Nebert 
et al 2003).
There is another clinically important issue likely to be 
associated with using SNPs for predicting drug response. 
Most human genes have approximately 3 to 10 major variant 
alleles, and potentially hundreds of rare variant alleles 
(Carlson et al 2003). Thus, subjects having rare alleles would 
probably not be discovered prior to receiving the drug and 
would potentially be at risk of receiving suboptimal therapy 
(Nebert et al 2003). The clinical implications of this situation 
require further consideration.
In light of these caveats, methodologies based on geno-
typing may be limited in situations where the environmental 
inﬂ  uences on drug efﬁ  cacy and toxicity are signiﬁ  cant. In 
cases where multiple genes contribute signiﬁ  cantly to the 
phenotypes, there will be additional complications. Firstly, 
the pharmacogenomic tests will be more complicated 
than those currently used, both in terms of genotyping 
and interpretation. The interpretation will be further com-
plicated if there are interactions between the genotypes, 
which affect the efﬁ  cacy/toxicity (ie, if the genes do not 
have independent inﬂ  uences on the phenotype). Secondly, 
the sample sizes to identify and validate the complement 
of genetic variations affecting efﬁ  cacy/toxicity would be 
much greater.
In the future, it is likely that alternative technologies such 
as metabonomics will be used to complement genotyping 
strategies for the prediction of drug response. Metabonom-
ics is a rapidly emerging science, involving the analysis of 
bioﬂ  uids including urine and plasma, in order to reﬂ  ect whole 
organism biochemical proﬁ  les and regulation of function 
(Nicholson 2002). The technique combines the use of multi-
variate statistics with an analytical platform, usually nuclear 
magnetic resonance (NMR) or liquid-chromatography-mass 
spectrometry. Its advantages include highly sensitive real 
time monitoring of the physiological and biochemical status, 
relative economy after an initial outlay for the analytical 
infrastructure and the ability to incorporate environmental 
inﬂ  uences. Besides being able to predict drug response 
a priori, this technology may be used for early detection of 
drug response and technology.
Determine reproducible association 
across ethnic populations
If the initial association between a SNP and drug phenotype 
is detected in a single ethnic group, it is important to assert 
that this association is also valid in other ethnic groups. If the 
association is valid only in a single ethnic group, this will 
cause difﬁ  culties in implementation of the pharmacogenomic 
test. In these cases, it will be imperative to ensure that the 
test is only applied to the speciﬁ  c ethnic group, a difﬁ  cult 
undertaking given the dramatic increase in interbreeding 
between people of differing ethnic backgrounds (Nebert and 
Vesell 2004; Shah 2004). Implementation of such a restrictive 
approach may also raise signiﬁ  cant ethical and regulatory 
challenges in some countries (Lee 2005; Buckley and 
McKinnon 2004). For example, in Australia where medicines 
are highly subsidized by the Federal Government on the basis 
of a rigorous assessment of cost-effectiveness, it is possible 
to envisage a scenario where subsidy could potentially be 
restricted along ethnic lines. The social acceptability of such 
a scenario is unclear and warrants further consideration.
There are a number of reasons why the pharmacoge-
nomic value of a SNP may vary between ethnic groups. 
Firstly, it is known that most genes have large differences 
in allelic frequencies across ethnic groups (Nebert and 
Menon 2001; Salsbury et al 2003). This can signiﬁ  cantly 
affect the cost-effectiveness of the test. Furthermore, for 
most genotype-phenotype associations, the SNP has not 
been proven to actually cause the variation in phenotype. 
The SNP may simply be in linkage disequilibrium with 
the causal genotype. This situation will become even more 
common with increasing use of genome-wide scanning of 
associated SNPs, using technologies such as SNP chips. 
The problem arises due to the variation in haplotype blocks 
between ethnic groups (Carlson et al 2003; Crawford et al 
2004). Therefore if the SNP is not causal, there is a good 
chance that the SNP may not be associated with other ethnic 
groups. Finally, it is possible that the underlying physiology 
may differ among ethnic groups due to different gene-gene 
and gene-environment interactions (Tate and Goldstein Therapeutics and Clinical Risk Management 2007:3(5) 756
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2004). Thus it is important to study the SNP-phenotype 
association in multiple ethnic groups.
Propose a speciﬁ  c protocol of how 
the genotyping will be used to guide 
clinical practice
It is not sufﬁ  cient to have an association between a SNP 
and the drug response. Widespread clinical usage of the 
association will require a well-deﬁ  ned protocol on exactly 
how the genotype information will be used to guide dos-
age and/or drug selection. It is important to emphasise that 
it is a particular pharmacogenomic protocol that must be 
validated prior to clinical implementation, not simply the 
association between the SNP and a given drug response. 
Collecting data and retrospectively optimizing a protocol 
gives a biased representation of the pharmacogenomic test’s 
utility. The hypothesis (ie, the pharmacogenomic protocol) 
should be completely deﬁ  ned prior to testing its validity. This 
is standard practice in clinical medicine and it is imperative 
that pharmacogenomics also adhere to good scientiﬁ  c and 
clinical practice.
Prospectively collect data to assess 
the cost-effectiveness of a speciﬁ  c 
pharmacogenomic protocol vs. the 
current standard practice: preferably 
a randomized controlled study
Cost-effectiveness of a pharmacogenomics test is generally 
enhanced in situations in which the association between 
genotype and clinical phenotype is strong and well estab-
lished (Veenstra et al 2000). Many reviews on clinical 
pharmacogenomics point to the lack of good evidence as a 
major factor underlying slow acceptance of many pharma-
cogenomic associations (Ensom 2001; Meyer 2004; Gardiner 
and Begg 2005).
In many cases the evidence for a genotype-phenotype 
association comes from a retrospective study in which 
multiple hypotheses are tested. Prior to clinical implementa-
tion, large prospective hypothesis-driven studies in multiple 
ethnic groups are required. If possible, it is highly preferable 
to randomize patients to either (i) pharmacogenomic guided 
treatment or (ii) the current standard method of drug and dose 
selection. This will allow for the most valid assessment of 
whether the particular pharmacogenomic protocol should 
supersede current clinical practice.
Analysis of these prospective studies is complicated. 
Systematic methods for assessing the costs and benefits 
associated with pharmacogenomic tests are available, 
but generally underused (Phillips et al 2003). There 
are strong economical pressures in health care and as a 
minimum a pharmacogenomic protocol must be shown to 
have greater overall benefit than cost. The costs and ben-
efits associated with different health alternatives can be 
complex and difficult to compare. Cost-benefit analysis 
and cost-effectiveness analysis are frameworks that are 
widely used to aid decisions regarding the use of health 
technologies (Veenstra et al 2000; Phillips et al 2003). 
Should the developers of pharmacogenomic tests wish to 
compete for finite healthcare funding, it will be necessary 
to demonstrate the worth of a specific pharmacogenomic 
protocol using these standard frameworks.
Engagement with and endorsement 
by the appropriate stakeholders for 
use of pharmacogenomic tests
Pharmacogenomics is unlikely to ﬂ  ourish unless all stake-
holders are involved and their concerns acknowledged. As 
a general rule, products of new technology tend to progress 
through a technology adoption life cycle, during which they 
sequentially penetrate different segments of the required 
uptake chain. These segments can differ dramatically in 
their preparedness to adopt and therefore require unique 
strategies in order to ensure uptake. The delivery of opti-
mal drug therapy involves many groups, which makes this 
issue particularly complicated. Patients and their families, 
medical practitioners, allied health groups, pathology pro-
viders, government regulatory agencies, groups providing 
therapeutic advice, ethicists and health funding agencies 
can all be identiﬁ  ed as stakeholders in pharmacogenomics. 
Each of these groups is likely to have different concerns 
and barriers to their involvement in pharmacogenomics. 
Furthermore, the concerns of different groups may not 
coincide.
The lay view of pharmacogenomics indicates that there 
is great concern that drugs developed within a pharmacoge-
nomic framework would be more expensive (Almarsdottir 
et al 2005). There is also general concern that pharmacoge-
nomics would lead to further inequalities between rich and 
poor countries and within societies (Almarsdottir et al 2005). 
A failure to address these identiﬁ  ed lay concerns will inevi-
tably limit uptake of pharmacogenomic tests.
Food and drug administration (FDA)
There is clear evidence that over recent times, the FDA is 
working to ensure a regulatory framework that is cognizant Therapeutics and Clinical Risk Management 2007:3(5) 757
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of pharmacogenomics. Clearly, pharmacogenomic tests 
with FDA approval are likely to generate conﬁ  dence in the 
utility of the test and as a result, this is likely to put positive 
pressure on their clinical uptake. There are also indications 
that the FDA is encouraging pharmaceutical companies to 
conduct pharmacogenomic research during the develop-
ment of new drugs and voluntarily submit the resulting data 
(Hampton 2005). This is more likely for adverse events. The 
current ﬁ  nancial models for drug development ensure that 
the developers of new drug products will generally prefer to 
maximize the population of people approved to use a given 
drug. As a result, it can be assumed that drug developers will 
be concerned that pharmacogenomic information could be 
used to keep a drug off the market or limit its use to a spe-
ciﬁ  c patient sub-population (Hampton 2005). The reduction 
in gross sales may be further exacerbated if the cost of the 
pharmacogenomic test becomes closely linked with the cost 
of the drug (Danzon and Towse 2002).
It is clear that the FDA plans to play an important role 
in regulating pharmacogenomic tests. Indeed, recently 
the FDA delayed the sale of a pharmacogenomics test for 
genetic variations inﬂ  uencing drug metabolism, citing the 
need for appropriate pre-market determination by the FDA 
(Hampton 2005).
Implement pharmacogenomic test 
in a staged manner
Staged implementation
Successful development of a widely used pharmacogenomic 
test is most likely to proceed in a staged manner. Such an 
approach relies on moving from the easiest site of imple-
mentation to the most difﬁ  cult and also, from the smallest 
target group to the largest. Thus, it is likely that successful 
pharmacogenomic development will begin in the setting of 
a major teaching hospital, progress through other hospital 
environments and then to broader medical environments.
Pharmacogenomic infrastructure
A number of the barriers to clinical pharmacogenomics are 
related to infrastructure. This includes the ethical and politi-
cal frameworks, the re-education of many different groups 
in the health sector, and the physical infrastructure for the 
pharmacogenomic tests. These particular barriers are not spe-
ciﬁ  c to particular pharmacogenomic tests. Once the general 
infrastructure is set up for a single pharmacogenomic test, 
further tests will require only relatively minor adjustments 
to the infrastructure. The problem is making the case for the 
initial investment.
Education
Education of health professionals is likely to pose a consider-
able barrier to the widespread uptake of pharmacogenomics. 
For example, surveys of tertiary pharmacy institutions in the 
US (Brock et al 2002) and community pharmacists (Sansgiry 
and Kulkarni 2003) show that contemporary genomic-based 
education is generally lacking across the pharmacy profession. 
In light of the perceived lack of pharmacogenomic education 
among various health care professionals, the International 
Society of Pharmacogenomics (ISP) has recently issued a 
call for pharmacogenomics to be incorporated immediately 
into the core curricula of medical, pharmaceutical and health 
science programs (Gurwitz et al 2005).
It can however be argued that pharmacogenomics is 
intuitively very similar to traditional therapeutic drug 
monitoring (TDM) with which most medical practitioners 
and pharmacists feel comfortable. In the case of TDM, drug 
measurements are used to guide optimal dosage selection. 
In the case of pharmacogenomics, biological measurements 
are used to guide optimal drug selection and dosage. It is 
the nature of the measurements that pose the educational 
challenges. It is true that genotype data is different from most 
other test results with which clinicians are familiar. Those 
without experience in dealing with genotypes and haplotypes 
can easily ﬁ  nd this information intimidating, confusing and 
frustrating. There are also some idiosyncrasies of this data 
that need to be understood for proper interpretation. How-
ever, for the most part, a basic understanding of the concepts 
can be quickly attained. While the facility that performs the 
pharmacogenomic tests would give some interpretation of the 
results, it is imperative to have someone physically present 
in the clinical environment with the depth of knowledge to 
ensure the data is used properly. This person could also serve 
in an educational role. The clinical pharmacist seems best 
suited to this role. A clinical pharmacist well versed in the 
interpretation of pharmacogenomic tests would take a large 
burden off the physicians and nurses, and facilitate a smooth 
transition to using these tests. In addition, it is important 
that the clinical pharmacist be able to integrate genotype 
information into existing knowledge of other factors that can 
signiﬁ  cantly affect pharmacotherapy (eg, food, concomitant 
medications, pathological conditions, gender, age, weight, 
environment) in order to develop the optimal treatment 
plan for each individual. It is unlikely that current training 
during pharmacy degrees will be sufﬁ  cient for this purpose, 
and post-graduate pharmacogenomics courses will need to 
be developed to enable efﬁ  cient and accurate interpretation 
of the test results.Therapeutics and Clinical Risk Management 2007:3(5) 758
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Ethical issues
There are many expressed concerns about the ethical issues 
surrounding use of genetic information in medicine. In the 
context of pharmacogenomics, this is probably of greater 
importance to genetic tests that are predictive of efﬁ  cacy 
rather than adverse events. As ethical issues in pharma-
cogenomics have begun to be dissected, there is recogni-
tion that the ethical issues related to pharmacogenomics are 
similar in character to ethical issues raised by other clinical 
circumstances. However, the prospect of individualised or 
personalised medicine brings many of these issues into clear 
focus. These ethical issues generally fall into three broad 
categories: the equitable provision of healthcare, the possi-
bility that genetic variants may track with race or ethnicity, 
and the questions of consent, access and privacy surrounding 
pharmacogenomic information.
It is true that in many clinical settings, there is a gen-
eral stigma associated with genetic testing. Even when 
the genetic test will give no more information than an 
equivalent phenotyping assay, most people will probably 
feel more comfortable with a phenotyping alternative. 
Alternative technologies such as metabonomics will 
not face this stigma. Metabonomic research will result 
in associations between (generally endogenous) chemi-
cal concentrations in biofluids (most commonly blood 
or urine) and the drug phenotype. Once the chemical 
is identified, a simple chemical assay for the specific 
chemical can be developed using technologies that are 
standard in pathology labs. Although not discovered using 
metabonomics, the measurement of serum creatinine 
concentrations to adjust the dosage of many drugs is a 
prime example of the type of tests this approach will result 
in. Tests for serum creatinine are undertaken routinely 
throughout the world without many of the concerns that 
surround genetic based tests.
Physical infrastructure
This mainly consists of instrumentation for genotyping. 
As costs for genotyping decrease, the greater the chance 
that pharmacogenomic tests with small to moderate utility 
will prove cost-effective. In the future it may be possible 
to undertake genotyping at point of care which will reduce 
costs associated with requiring a follow-up consultation 
(Phillips et al 2001). A current concern is the wide variation 
in the cost of genotyping (Gardiner and Begg 2005), which 
is likely to be partially responsible for variable uptake of 
some well studied pharmacogenomic tests such as that for 
thiopurine methyltransferase (TMPT). It has been suggested 
that widespread clinical uptake of trastuzumab was enabled 
by the approval of a standardized, simple and commercially 
available method. Whether this extrapolates to other phar-
macogenomics test is uncertain due to the abundance of 
differing technologies for genotyping.
Synergy with information technology
As information technology is further integrated into the 
day-to-day working of the health professions, new opportuni-
ties for pharmacogenomics will arise. Integrating complex 
pharmacogenomic data with conventional factors places 
an increased burned on health professions involved with 
optimizing the pharmacotherapy of individual patients. It is 
expected that decision support software will be developed 
to aid in this process. This will become especially important 
for the multi-gene pharmacogenomic protocols (potentially 
incorporating other technologies) expected in the future.
Conclusion
The greater the barriers to the clinical adoption of pharma-
cogenomics, the greater the evidence and size of the improve-
ment in clinical outcome required. The problem to date is 
that the evidence and importance of most pharmacogenomic 
associations are not sufﬁ  cient to overcome the barriers to the 
clinical implementation. Fortunately, a number of barriers 
to clinical utilization are not speciﬁ  c to particular pharma-
cogenomic tests and are likely to be signiﬁ  cantly reduced 
with time. For example, technological advances are likely to 
improve the availability and reproducibility and decrease the 
difﬁ  culty and cost of genotyping. In addition, some barriers 
are one-off costs. Predominant among these are pharmacoge-
nomic education of clinicians and the general public, and 
the development of general ethical protocols and ﬁ  nancial 
frameworks for clinical pharmacogenomics.
Most pharmacogenomic associations do not proceed 
past the second step on the road to clinical implementation. 
Why this is the case is not clear. Perhaps it is indifference 
following discovery of the initial SNP-phenotype associa-
tion. Perhaps it is a lack of knowledge of how to proceed. 
Perhaps, because the SNP-association studies are not strong 
enough to be cost-effective.
It is obvious that much room remains to improve the 
use of pharmacotherapy. However, it is not apparent that 
pharmacogenomics as it currently stands will be able to 
signiﬁ  cantly improve pharmacotherapy for the majority of 
drugs. There are many critical factors in to which pharma-
cogenomics can provide little insight. Chief among these 
are environmental inﬂ  uences (including interactions with Therapeutics and Clinical Risk Management 2007:3(5) 759
Barriers to clinical pharmacogenomics
foods, natural therapies and other drugs) and behavioral 
factors that inﬂ  uence compliance with treatment regimens 
(Ensom 2001). Together, these are probably responsible for 
a signiﬁ  cant proportion of the detrimental inter-individual 
variability resulting in poor efﬁ  cacy and toxicity. It is likely 
that complementary technologies, such as metabonomics 
will be able to compensate for some limitations of genotype-
phenotype associations.
As infrastructure becomes better established and phar-
macogenomics becomes thought of as simply another test 
that can guide therapy, rather than a radical technology that 
raises concern it is likely that the balance between costs 
and beneﬁ  ts will shift in favor of clinically implementing 
pharmacogenomic protocols.
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